ArticleMediators of inflammation2026
Mendelian Randomization Identified SLC2A9 as a Novel cis-eQTL-Mediated Susceptibility Gene in Suppressing Renal Cancer and Its Related Metabolic Mechanisms.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mendelian Randomization Identified SLC2A9 as a Novel cis-eQTL-Mediated Susceptibility Gene in Suppressing Renal Cancer and Its Related Metabolic Mechanisms.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMendelian randomization (MR) analysis has currently been widely used in combination with expression quantitative trait loci (eQTLs) or cis-eQTLs for identifying novel drug targets in various diseases. Hence in this article, we first integrated MR analysis with eQTLs and cis-eQTLs to reveal the causal effects among SLC2A9 and renal cancer (RC), along with its related metabolic mechanisms.
methodsRelated genome-wide association study (GWAS) data were obtained from online datasets. Two-sample MR and summary-data-based MR study (SMR) analyses were applied to assess the causal effects among SLC2A9 eQTL or cis-eQTLs and RC, respectively. Sensitivity analysis confirmed the robustness and heterogeneity of the results. Besides, 1400 metabolites were enrolled as mediators to further reveal the related metabolic mechanisms of SLC2A9 eQTL involved in RC.
resultsOur results found that SLC2A9 eQTL was markedly associated with low risks of RC in the IEU OpenGWAS eQTLs dataset (discovering) (p = 0.030). The eQTLGEN and GTEx Whole Blood datasets validated the causal effects among SLC2A9 cis-eQTL and RC, reducing RC risks (both p < 0.05). The TCGA-KIRC and the CPTAC-KIRC datasets validated the mRNA and protein expression levels of SLC2A9 in RC, confirming its antitumor roles in RC (both p < 0.05). A total of five metabolites were finally identified to reveal the related metabolic mechanisms of SLC2A9 eQTL involved in RC (all p < 0.05).
conclusionsThis study indicated that SLC2A9 eQTL or cis-eQTL was markedly associated with low risks of RC and played an antitumor role in RC, along with preliminary identification of five metabolic pathways for its potential mechanisms requiring further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.